Skip to main content
SpringerLink
Log in

Tobacco Use Disorder

  • Chapter
  • First Online:
Psychotic Disorders

Part of the book series: Current Clinical Psychiatry ((CCPSY))

  • 1634 Accesses

Abstract

The majority of patients with schizophrenia currently smokes or has smoked in the past, at much higher rates than seen in the general population. Psychiatry needs to make smoking cessation a priority and help their patients quit smoking and remain quit. In this chapter, I discuss the assessment of smoking and treatment tools for successful smoking cessation for patients with serious mental disorders. Emphasis is placed on the use of pharmacotherapy, particularly varenicline, and opt-out care, with treatment being the default option in a chronic disease model. E-cigarettes may be a harm reduction option for patients seriously addicted to cigarettes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Quote Investigator. It’s easy to quit smoking. I have done it a thousand times. Available at: https://quoteinvestigator.com/2012/09/19/easy-quit-smoking/. Accessed 1 July 2019.

  2. Dickerson F, Schroeder J, Katsafanas E, Khushalani S, Origoni AE, Savage C, et al. Cigarette smoking by patients with serious mental illness, 1999–2016: an increasing disparity. Psychiatr Serv. 2018;69:147–53.

    Article  PubMed  Google Scholar 

  3. Freudenreich O, MacLaurin SA, Irwin KI, Cather C, Schnitzer KM, Paude S, et al. Smoking cessation in serious mental illness: a multi-pronged approach using the treatment cascade framework. 27th European Congress of Psychiatry, Warsaw, Poland, April 6–9, 2019.

    Google Scholar 

  4. Massachusetts Department of Public Health. Massachusetts Tobacco Cessation and Prevention Program (MTCP). Available from: https://www.mass.gov/massachusetts-tobacco-cessation-and-prevention-program-mtcp. Accessed 1 July 2019.

  5. Wang TW, Asman K, Gentzke AS, Cullen KA, Holder-Hayes E, Reyes-Guzman C, et al. Tobacco product use among adults – United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:1225–32.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-Year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368:351–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Srihari VH, Phutane VH, Ozkan B, Chwastiak L, Ratliff JC, Woods SW, et al. Cardiovascular mortality in schizophrenia: defining a critical period for prevention. Schizophr Res. 2013;146:64–8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Stubbs B, Vancampfort D, Bobes J, De Hert M, Mitchell AJ. How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview. Acta Psychiatr Scand. 2015;132:122–30.

    Article  CAS  PubMed  Google Scholar 

  9. Prochaska JJ, Hall SM, Bero LA. Tobacco use among individuals with schizophrenia: what role has the tobacco industry played? Schizophr Bull. 2008;34:555–67.

    Article  PubMed  Google Scholar 

  10. Quisenaerts C, Morrens M, Hulstijn W, de Bruijn E, Timmers M, Streffer J, et al. The nicotinergic receptor as a target for cognitive enhancement in schizophrenia: barking up the wrong tree? Psychopharmacology. 2014;231:543–50.

    Article  CAS  PubMed  Google Scholar 

  11. Robson D, Spaducci G, McNeill A, Stewart D, Craig TJK, Yates M, et al. Effect of implementation of a smoke-free policy on physical violence in a psychiatric inpatient setting: an interrupted time series analysis. Lancet Psychiatry. 2017;4:540–6.

    Article  PubMed  Google Scholar 

  12. Gurillo P, Jauhar S, Murray RM, MacCabe JH. Does tobacco use cause psychosis? Systematic review and meta-analysis. Lancet Psychiatry. 2015;2:718–25.

    Article  PubMed  PubMed Central  Google Scholar 

  13. MacLaurin SA, Henderson DC, Freudenreich O. Delineating responsibility: primary care provider perspective. Psychiatr Serv. 2015;66:333.

    Article  PubMed  Google Scholar 

  14. Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, Goff DC, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA. 2014;311:145–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Barua RS, Rigotti NA, Benowitz NL, Cummings KM, Jazayeri MA, Morris PB, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2018;72:3332–65.

    Article  PubMed  Google Scholar 

  16. Wagner EH. Chronic disease management: what will it take to improve care for chronic illness? Eff Clin Pract. 1998;1:2–4.

    CAS  PubMed  Google Scholar 

  17. Blok DJ, de Vlas SJ, van Empelen P, van Lenthe FJ. The role of smoking in social networks on smoking cessation and relapse among adults: a longitudinal study. Prev Med. 2017;99:105–10.

    Article  PubMed  Google Scholar 

  18. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict. 1991;86:1119–27.

    Article  CAS  PubMed  Google Scholar 

  19. Richter KP, Ellerbeck EF. It’s time to change the default for tobacco treatment. Addiction. 2015;110:381–6.

    Article  PubMed  Google Scholar 

  20. Johnson EJ, Medicine GD. Do defaults save lives? Science. 2003;302:1338–9.

    Article  CAS  PubMed  Google Scholar 

  21. AHRQ. 5 major steps to intervention. Available from: https://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/tobacco/5steps.html. Accessed 1 July 2019.

  22. Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot. 1997;12:38–48.

    Article  CAS  PubMed  Google Scholar 

  23. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387:2507–20.

    Article  CAS  PubMed  Google Scholar 

  24. Beyens MN, Guy C, Mounier G, Laporte S, Ollagnier M. Serious adverse reactions of bupropion for smoking cessation: analysis of the French Pharmacovigilance Database from 2001 to 2004. Drug Saf. 2008;31:1017–26.

    Article  CAS  PubMed  Google Scholar 

  25. Macaluso M, Zackula R, D’Empaire I, Baker B, Liow K, Preskorn SH. Twenty percent of a representative sample of patients taking bupropion have abnormal, asymptomatic electroencephalographic findings. J Clin Psychopharmacol. 2010;30:312–7.

    Article  PubMed  Google Scholar 

  26. Cather C, Pachas GN, Cieslak KM, Evins AE. Achieving smoking cessation in individuals with schizophrenia: special considerations. CNS Drugs. 2017;31:471–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA. 2014;311:155–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Gaballa D, Drowos J, Hennekens CH. Smoking cessation: the urgent need for increased utilization of varenicline. Am J Med. 2017;130:389–91.

    Article  PubMed  Google Scholar 

  29. Tsoi DT, Porwal M, Webster AC. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2010;196:346–53.

    Article  PubMed  Google Scholar 

  30. Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res. 2012;14:343–50.

    Article  CAS  PubMed  Google Scholar 

  31. Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae TD, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015;313:687–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Chapman S, MacKenzie R. The global research neglect of unassisted smoking cessation: causes and consequences. PLoS Med. 2010;7:e1000216.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Monitoring the Future. Available at: http://www.monitoringthefuture.org/pressreleases/18drugpr.pdf. Accessed 1 July 2019.

  34. Leventhal AM, Strong DR, Kirkpatrick MG, Unger JB, Sussman S, Riggs NR, et al. Association of electronic cigarette use with initiation of combustible tobacco product smoking in early adolescence. JAMA. 2015;314:700–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Fairchild AL, Bayer R, Colgrove J. The renormalization of smoking? E-cigarettes and the tobacco "endgame". N Engl J Med. 2014;370:293–5.

    Article  CAS  PubMed  Google Scholar 

  36. Primack BA, Soneji S, Stoolmiller M, Fine MJ, Sargent JD. Progression to traditional cigarette smoking after electronic cigarette use among US adolescents and young adults. JAMA Pediatr. 2015;169:1018–23.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Levy DT, Warner KE, Cummings KM, Hammond D, Kuo C, Fong GT, et al. Examining the relationship of vaping to smoking initiation among US youth and young adults: a reality check. Tob Control. 2018. https://doi.org/10.1136/tobaccocontrol-2018-054446.

    Article  PubMed  Google Scholar 

  38. Miller BJ, Wang A, Wong J, Paletta N, Buckley PF. Electronic cigarette use in patients with schizophrenia: prevalence and attitudes. Ann Clin Psychiatry. 2017;29:4–10.

    PubMed  Google Scholar 

  39. Malas M, van der Tempel J, Schwartz R, Minichiello A, Lightfoot C, Noormohamed A, et al. Electronic cigarettes for smoking cessation: a systematic review. Nicotine Tob Res. 2016;18:1926–36.

    Article  PubMed  Google Scholar 

  40. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, et al. A randomized trial of e-cigarettes versus nicotine-replacement therapy. N Engl J Med. 2019;380:629–37.

    Article  PubMed  Google Scholar 

  41. Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med. 2016;4:116–28.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Abrams DB. Promise and peril of e-cigarettes: can disruptive technology make cigarettes obsolete? JAMA. 2014;311:135–6.

    Article  CAS  PubMed  Google Scholar 

  43. Prochaska JJ. Nicotine replacement therapy as a maintenance treatment. JAMA. 2015;314:718–9.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open. 2014;4:e004216.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Anderson GD, Chan LN. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet. 2016;55:1353–68.

    Article  CAS  PubMed  Google Scholar 

  46. Lowe EJ, Ackman ML. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother. 2010;44:727–32.

    Article  CAS  PubMed  Google Scholar 

  47. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther. 2004;76:178–84.

    Article  CAS  PubMed  Google Scholar 

  48. Thorndike AN, Achtyes ED, Cather C, Pratt S, Pachas GN, Hoeppner SS, et al. Weight gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with serious mental illness: a subgroup analysis of a randomized trial. J Clin Psychiatry. 2016;77:e320–6.

    Article  PubMed  Google Scholar 

  49. McElroy SL. The dual epidemic of tobacco dependence and obesity among those with severe mental illness. J Clin Psychiatry. 2016;77:e327–8.

    Article  PubMed  Google Scholar 

  50. Hurt RT, Croghan IT, Schroeder DR, Hays JT, Choi DS, Ebbert JO. Combination varenicline and lorcaserin for tobacco dependence treatment and weight gain prevention in overweight and obese smokers: a pilot study. Nicotine Tob Res. 2017;19:994–8.

    CAS  PubMed  Google Scholar 

  51. Esterberg ML, Compton MT. Smoking behavior in persons with a schizophrenia-spectrum disorder: a qualitative investigation of the transtheoretical model. Soc Sci Med. 2005;61:293–303.

    Article  PubMed  Google Scholar 

  52. McDermott MS, Marteau TM, Hollands GJ, Hankins M, Aveyard P. Change in anxiety following successful and unsuccessful attempts at smoking cessation: cohort study. Br J Psychiatry. 2013;202:62–7.

    Article  PubMed  Google Scholar 

  53. Cather C, Hoeppner S, Pachas G, Pratt S, Achtyes E, Cieslak KM, et al. Improved depressive symptoms in adults with schizophrenia during a smoking cessation attempt with varenicline and behavioral therapy. J Dual Diagn. 2017;13:168–78.

    Article  PubMed  Google Scholar 

  54. Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc. 2005;80:652–6.

    Article  CAS  PubMed  Google Scholar 

  55. Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med. 2018;178:622–31.

    Article  PubMed  PubMed Central  Google Scholar 

Additional Resources

    Web Sites

    • https://www.cdc.gov/tobacco – The smoking and tobacco use site put out by the Centers for Disease Control and Prevention.

    • https://smokefree.gov/ – Refer all patients, assuming they use computers or smart phones, to this US Government website from the National Cancer Institute.

    • https://www.becomeanex.org/ – A web-based support program by the non-profit Truth Initiative that has set out to create a smoke-free culture in America, targeting our youth and young adults so they do not become the next generation of smokers.

    Articles

    • Barua RS, Rigotti NA, Benowitz NL, Cummings KM, Jazayeri MA, Morris PB, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2018;72:3332–65. – Very well organized document by the American College of Cardiology about how everything you need to know about smoking cessation, including assessment and pharmacology.

      Article  PubMed  Google Scholar 

    • Cather C, Pachas GN, Cieslak KM, Evins AE. Achieving smoking cessation in individuals with schizophrenia: special considerations. CNS Drugs. 2017;31:471–81. – An excellent review of smoking cessation with special consideration for patients with schizophrenia; from my hospital’s own smoking cessation program.

      Article  CAS  PubMed  PubMed Central  Google Scholar 

    • Chapman S. E-cigarettes: the best and the worst case scenarios for public health. BMJ. 2014;349:g5512. – A very readable essay about e-cigarettes from a public health perspective.

      Article  PubMed  Google Scholar 

    • Siegel DA, Jatlaoui TC, Koumans EH, Kiernan EA, Layer M, Cates JE, et al. Update: interim guidance for health care providers evaluating and caring for patients with suspected e-cigarette, or vaping, product use associated lung injury – United States, October 2019. MMWR Morb Mortal Wkly Rep. 2019;68:919–927. – Concerns about lung injuries (including deaths) related to vaping have emerged as vaping has become more widespread, tempering my enthusiasm for vaping as a tool to help patients quit or switching to e-cigarettes.

      Google Scholar 

    Download references

    Author information

    Authors and Affiliations

    1. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

      Oliver Freudenreich

    Authors
    1. Oliver Freudenreich
      View author publications

      You can also search for this author in PubMed Google Scholar

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2020 Springer Nature Switzerland AG

    About this chapter

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this chapter

    Freudenreich, O. (2020). Tobacco Use Disorder. In: Psychotic Disorders. Current Clinical Psychiatry. Humana, Cham. https://doi.org/10.1007/978-3-030-29450-2_27

    Download citation

    • DOI: https://doi.org/10.1007/978-3-030-29450-2_27

    • Published:

    • Publisher Name: Humana, Cham

    • Print ISBN: 978-3-030-29449-6

    • Online ISBN: 978-3-030-29450-2

    • eBook Packages: MedicineMedicine (R0)

    Publish with us

    Policies and ethics

    Search

    Navigation